cardiac surgery News
-
You live and learn
To better understand the needs of new medical markets, it has great importance for us to directly talk to end users. One of these end users is Prof. Reuthebuch who is Deputy Senior Physician of Cardiac Surgery in the university hospital in Basel. Together with him, we have evaluated in which part of a transcatheter heart valve implantation our navigation technology could provide benefits. This ...
-
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Professor Daniel Wendt, MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022. Dr. Wendt is an internationally renowned academic cardiac surgeon with over ...
-
Berlin Heart triples staff member donations and secures `Films for life` project financing
For many Berlin Heart staff members, providing ventricular assist devices for people who are waiting for a donor heart is more than just a job. Extending the lives of patients and giving them quality of life despite all circumstances is the motivation that drives many Berlin Heart staff members on a daily basis. Raising awareness for the issue of organ donation is therefore close to their hearts, ...
-
Potrero Medical Names Vanessa Moll, MD, PhD, FCCM, FASA as Chief Medical Officer
Potrero Medical, innovator of the Accuryn Monitoring System, a sensory integrated foley catheter that provides real-time, actionable information to health care providers so they can take steps to prevent critical conditions such as acute kidney injury (AKI), announced that Vanessa Moll, MD, PhD, FCCM, FASA has joined the executive leadership team as its Chief Medical Officer (CMO). Dr. Moll ...
-
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced the public availability of preliminary data abstracts from two separate endocarditis studies, including the REMOVE study, to be presented at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) annual meeting ...
-
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Ticagrelor (STAR–T) double-blind, randomized, controlled clinical trial ...
-
Stanford Physicians Continue to Rely on EchoPixel’s Technology
EchoPixel has had a long-standing relationship with Stanford physicians, who were early adopters of its technology, beginning with the successful surgery of the conjoined Sandoval twins in 2017. The affiliation has continued in partnership with Michael Ma, MD, Assistant Professor of Cardiothoracic Surgery in the Division of Pediatric Cardiac Surgery at Stanford University, who has used ...
-
Novel String-Shaped Implantable Defibrillator Proves Effective - In Treating Patients with Irregular Heartbeats
CHICAGO, May 12, 2017 - A new study examines the effectiveness of the Implantable Subcutaneous String Defibrillator (ISSD™), a flexible, string-shaped and first-ever rechargeable implantable cardioverter-defibrillator (ICD). This is the first-in-man study to report on the feasibility of the innovative device and was presented today at Heart Rhythm 2017, the Heart Rhythm Society's 38th ...
By NewPace Ltd.
-
AtriCure Reports Second Quarter 2021 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward making our platforms the standard of ...
-
Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting
BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...
-
CytoSorbents To Expand Direct Sales of CytoSorb to the United Kingdom, the Sixth Largest Medical Device Market in the World
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via ...
-
CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor
CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients. The capital increase is subscribed by returning investors joined by the EIC Fund, the European Commission's venture capital mega-fund, which makes its first investment. CorWave, located in Clichy, Île-de-France, is developing ...
By CorWave
-
Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada
The Institut universitaire de cardiologie et de pneumologie de Québec–Université Laval (the Institute) recently successfully performed a first case of percutaneous tricuspid replacement. So far, only 10 patients worldwide have undergone this type of percutaneous replacement. The procedure was performed by Dr. François Dagenais, cardiac surgeon and head of the Cardiac ...
-
CARMAT appoints Ivo Simundic as Sales director for the DACH region to support the deployment of the Aeson artificial heart in Germany, Austria and Switzerland
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the appointment of Ivo Simundic as Sales director for the DACH region (Germany, Austria and Switzerland). Graduated from ...
By Carmat
-
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. CytoSorbents will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18, 2021. Dr. ...
-
Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One
Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study. The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the ...
By Robocath
-
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate ...
-
Palisade Bio (Nasdaq: PALI) To Participate In The Virtual Investor Management And KOL Roundtable Event
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...
By Palisade Bio
-
£1.1 million project to develop new biodegradable stents
A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you